SciFi Futures
← Concepts
Neurotechnology

Intelligence amplification treatment

A one-off medical intervention that raises general intelligence far beyond the normal range in an adult brain.

In shortIntelligence amplification treatment, from Flowers for Algernon (Daniel Keyes, 1966), is at technology readiness level 2 of 9 (technology concept formulated) at its weakest link. Held back by Mechanistic theory of neural computation. Science status: consistent with known physics; key effects unproven at scale. Estimated new funding to unlock: $11B–52B (a floor; some parts are priced only to early research).

Charlie Gordon's surgery and enzyme therapy triples his IQ within months, with the gain later proving unstable and reversing.
Flowers for Algernon by Daniel Keyes, 1966Set in 1966Overdue60 years past the story's date; weakest link still at TRL 2

Closest todayStimulants and modafinil give small average gains in healthy adults; no intervention raises general intelligence durably.

Dependency stack

Research TRL 1–3Development TRL 4–6Deployment TRL 7–9
Sort by
  • Raising capacity requires knowing what physically limits cognition in the first place
    • Unknown sufficient level of biological detail
    plausibleTRL 2
    • Wiring diagrams constrain and test circuit models
      ✕3 blockers›
      • Human proofreading of AI segmentation dominates cost; 2025 methods imply tens of billions of dollars for one mouse brain
      • Imaging throughput and storage; a human brain at EM resolution is of order 100+ exabytes of raw data
      • Sectioning or expanding whole large brains without tissue loss or distortion
      TRL 3
      • Ultrastructure must survive preservation before it can be imaged
        ✕3 blockers›
        • Ischemic damage starts within minutes of circulatory arrest, before perfusion can begin
        • Aldehyde fixation may destroy molecular state (phosphorylation, receptor conformation) that could carry memory
        • No assay proves preserved tissue still contains the information an emulation would need
        TRL 4
      • Automated segmentation and tracing of exabyte-scale image volumes
        ✕2 blockers›
        • Grid power and interconnection queues
        • Advanced-node chip and HBM memory supply
        TRL 8
  • Large durable gains in healthy brains are exactly what has never been demonstrated
    ✕4 blockers›
    • Trade-offs; manipulations that raise one capacity (plasticity, excitability) usually cost another, such as pain sensitivity or stability
    • No molecular target identified that raises general cognitive capacity rather than arousal or motivation
    • Healthy-subject ceiling effects and inverted-U dose dependence on baseline ability
    • Measuring durable gain requires year-scale trials with no accepted endpoint
    plausibleTRL 3
    • Raising capacity requires knowing what physically limits it
      plausibleTRL 2
    • Durable interventions (gene therapy, biologics) must reach neurons brain-wide
      ✕3 blockers›
      • Receptor targeting is species-specific; capsids binding human TfR1 often fail in macaque
      • Pre-existing anti-AAV immunity excludes a large fraction of patients and blocks redosing
      • Dose needed for brain-wide coverage drives liver toxicity and manufacturing cost
      TRL 4
      • Designed capsid and shuttle proteins are the main route to receptor-specific transcytosis
        ✕1 blocker›
        • Designing catalysis and conformational dynamics
        TRL 6
  • Any durable agent must reach neurons brain-wide after a systemic dose
    TRL 4
  • A permanent change in neural function implies editing or regulating genes in adult neurons
    ✕2 blockers›
    • Delivery to tissues beyond liver
    • Long-term off-target safety
    TRL 6
  • Learning-rate gains are partly about how fast engrams form and consolidate
    ✕4 blockers›
    • Human engrams cannot be labeled; the mouse toolkit depends on transgenic c-fos tagging
    • Memory is distributed across an engram complex in many regions, not one addressable site
    • Writing content requires knowing the ensemble code for arbitrary experience, which is unknown
    • Specificity; stimulation that strengthens one memory also perturbs neighbours
    plausibleTRL 3

Who could unlock it

Mechanistic theory of neural computationTRL 2bottleneck
  • Philip ShiuResearcher, Eon Systems
    Built the leaky integrate-and-fire whole fly brain model that predicts sensorimotor circuit responses (Nature 2024)
  • Srinivas TuragaResearcher, HHMI Janelia Research Campus
    Co-led connectome-constrained networks that predict neural activity across the fly visual system (Nature 2024)
  • Larry AbbottResearcher, Columbia University
    Theoretical neuroscientist; co-director of the Zuckerman Institute's Center for Theoretical Neuroscience
  • Allen InstituteAcademic lab
    MICrONS functional connectomics and a 230,000-cell biophysical model of mouse visual cortex
Large-effect cognitive enhancement in healthy brainsTRL 3
  • Barbara SahakianResearcher, Department of Psychiatry, University of Cambridge
    Has run the longest-standing program of controlled trials of pharmacological cognitive enhancement in healthy volunteers, including the modafinil studies that anchor the current small effect-size estimates
  • Amy ArnstenResearcher, Yale School of Medicine
    Mapped the prefrontal catecholamine mechanisms that set working-memory capacity - the basis for guanfacine and for why dose-response curves in healthy brains are inverted-U rather than monotonic
  • Michael KahanaResearcher, University of Pennsylvania
    Showed closed-loop intracranial stimulation improving word recall in neurosurgical patients (2018), the largest verified memory-enhancement effect in humans to date
  • Shionogi (Tetra Therapeutics)Company
    Acquired Tetra in 2020 and is running the PDE4D inhibitor zatolmilast in cognition trials for fragile X syndrome - the furthest-advanced small molecule aimed directly at a memory mechanism, though targeted at disease rather than healthy brains
Systemic delivery of agents across the blood-brain barrierTRL 4
  • Benjamin DevermanResearcher, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard
    Engineered BI-hTFR1, an AAV9 capsid reprogrammed to bind human transferrin receptor, giving 40-50x more CNS expression than AAV9 in human TFRC knock-in mice (Science, 2024)
  • Denali TherapeuticsCompany
    Its TransportVehicle platform produced AVLAYAH (tividenofusp alfa), approved by the FDA in March 2026 as the first biologic specifically designed to cross the blood-brain barrier
  • Voyager TherapeuticsCompany
    Used its TRACER platform to find cross-species BBB-penetrant capsids and identified ALPL as the receptor they use; VCAP-102 gave 20-400x more brain gene transfer than AAV9 in primates (2025)
  • Sangamo TherapeuticsCompany
    Reported its STAC-BBB capsid achieving widespread brain transduction after intravenous dosing in non-human primates at clinically relevant doses (2024)
Precise in vivo gene editingTRL 6
  • Intellia TherapeuticsCompany
    Its Phase 3 HAELO trial of lonvo-z (NTLA-2002) in hereditary angioedema met the primary and all key secondary endpoints in April 2026, the first Phase 3 data for any in vivo gene-editing therapy
  • David LiuResearcher, Broad Institute of MIT and Harvard
    Invented base and prime editing; his lab designed the base editor used for baby KJ in 2025 and is extending prime editing to disease-agnostic suppressor-tRNA approaches
  • Kiran MusunuruResearcher, University of Pennsylvania and Children's Hospital of Philadelphia
    Led the first patient-specific in vivo base-editing therapy, an LNP-delivered editor given to an infant with CPS1 deficiency (NEJM, May 2025), and is building umbrella platforms for urea-cycle disorders and PKU
  • NIH Somatic Cell Genome Editing ConsortiumProgram
    NIH Common Fund program funding targeted delivery technologies, safety assays and platform clinical-trial pathways; it underwrote the preclinical work behind the KJ therapy

Beyond engineering

  • Enhancement of healthy adults has no regulatory approval pathway or accepted endpoint
  • Access inequality if the intervention is expensive and irreversible